FYI From Human Genome Sciences, Inc.: GlaxoSmithKline Announces Positive Data from Harmony 8 Phase 3 Trial and Completion of Clinical Registration Package for Albiglutide in Type 2 Diabetes

ROCKVILLE, Md.--(BUSINESS WIRE)--Attached is a press release issued earlier today by GlaxoSmithKline, announcing that data have been received from the Phase 3 Harmony 8 study and from the event-driven…
Read the full story: BioSpace.com Featured News